Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Metabolic Syndrome × Etanercept × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Metabolic Syndrome 1 Lung Neoplasms 1 Inflammation 1 Granulomatosis with Polyangiitis 1 Bone Neoplasms 1 Arthritis, Juvenile 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00111956 2017-10-06

Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2/3 Completed

Inflammation, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡